Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients
Authors' conclusion
Comorbid OSA is associated with a significant increase in total healthcare costs driven largely by outpatient and prescription costs. This burden was concentrated among patients with cardiovascular comorbidity and persisted among chronic GLP-1 RA users.
Study context
- Population
- Overweight to severely obese adults aged 18–64 years, IQVIA PharMetrics Plus commercial claims 2016–2025matched cohort
- Participants
- 27,942 participants
- Exposure
- Obstructive sleep apnea (OSA) vs non-OSA controls
- OSAn = 13,971
- Outcome
- Incremental total healthcare costs of OSA (adjusted cost ratio and AME)
- Follow-up
- 365-day follow up
Methodological detailspropensity-score matched 1:1, commercial claims data
- Propensity-score matched 1:1
- Commercial claims data
Main finding
As reported in the abstract
Adjusted cost ratio
1.24
95% CI 1.20–1.28
OSA
AME
$6942 per patient
OSA
Observational data: associations, not effects.
Further findings
Outpatient visit costs (incremental cost of OSA) · 365-day follow-up
- AME of outpatient visit costs
- $2955
Prescription costs (incremental cost of OSA) · 365-day follow-up
- AME of prescription costs
- $3198
Total healthcare costs, subgroup with cardiovascular disease (CVD) (incremental cost of OSA) · 365-day follow-up
- AME in patients with CVD
- $9257
Total healthcare costs, subgroup of chronic GLP-1 RA users (incremental cost of OSA) · 365-day follow-up
- AME in chronic GLP-1 RA users
- $12359
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →